The endocannabinoid CB1 receptor is known to have protective effects in kidney disease. The aim of the present study is to evaluate the potential agonistic and antagonistic actions and to determine the renoprotective potential of CB1 receptors in diabetic nephropathy. The present work investigates the possible role of CB1 receptors in the pathogenesis of diabetes-induced nephropathy. Streptozotocin (STZ) (55 mg/kg, i.p., once) is administered to uninephrectomised rats for induction of experimental diabetes mellitus. The CB1 agonist (oleamide) and CB1 antagonist (AM6545) treatment were initiated in diabetic rats after 1 week of STZ administration and were given for 24 weeks. The progress in diabetic nephropathy is estimated biochemically by measuring serum creatinine (1.28±0.03) (p < 0.005), blood urea nitrogen (67.6± 2.10) (p < 0.001), urinary microprotein (74.62± 3.47) (p < 0.005) and urinary albuminuria (28.31±1.17) (p < 0.0001). Renal inflammation was assessed by estimating serum levels of tumor necrosis factor alpha (75.69±1.51) (p < 0.001) and transforming growth factor beta (8.73±0.31) (p < 0.001). Renal morphological changes were assessed by estimating renal hypertrophy (7.38± 0.26) (p < 0.005) and renal collagen content (10.42± 0.48) (p < 0.001). From the above findings, it can be said that diabetes-induced nephropathy may be associated with overexpression of CB1 receptors and blockade of CB1 receptors might be beneficial in ameliorating the diabetes-induced nephropathy.

中文翻译：

---

内源性大麻素CB1受体在链脲佐菌素诱导的非全切除Wistar大鼠糖尿病性肾病中的作用

已知内源性大麻素CB1受体在肾脏疾病中具有保护作用。本研究的目的是评估糖尿病肾病中潜在的激动作用和拮抗作用，并确定CB1受体的肾脏保护潜力。本工作调查了CB1受体在糖尿病性肾病发病机制中的可能作用。将链脲佐菌素（STZ）（55 mg / kg，腹膜内注射，一次）施用于未切除直肠的大鼠，以诱导实验性糖尿病。给予STZ 1周后，在糖尿病大鼠中开始CB1激动剂（油酰胺）和CB1拮抗剂（AM6545）治疗，并给予24周。通过测量血清肌酐（1.28±0.03）（p <0.005），血尿素氮（67.6±2.10）（p <0.001）来生化评估糖尿病肾病的进展，尿微量蛋白（74.62±3.47）（p <0.005）和尿蛋白尿（28.31±1.17）（p <0.0001）。通过估计血清肿瘤坏死因子α（75.69±1.51）（p <0.001）和转化生长因子β（8.73±0.31）（p <0.001）的血清水平来评估肾脏炎症。通过估计肾肥大（7.38±0.26）（p <0.005）和肾胶原含量（10.42±0.48）（p <0.001）评估肾脏形态变化。从以上发现，可以说糖尿病引起的肾病可能与CB1受体的过表达有关，而阻断CB1受体可能在减轻糖尿病引起的肾病方面是有益的。通过估计血清肿瘤坏死因子α（75.69±1.51）（p <0.001）和转化生长因子β（8.73±0.31）（p <0.001）的血清水平来评估肾脏炎症。通过估计肾肥大（7.38±0.26）（p <0.005）和肾胶原含量（10.42±0.48）（p <0.001）评估肾脏形态变化。从以上发现，可以说糖尿病引起的肾病可能与CB1受体的过表达有关，而阻断CB1受体可能在减轻糖尿病引起的肾病方面是有益的。通过估计血清肿瘤坏死因子α（75.69±1.51）（p <0.001）和转化生长因子β（8.73±0.31）（p <0.001）的血清水平来评估肾脏炎症。通过估计肾肥大（7.38±0.26）（p <0.005）和肾胶原含量（10.42±0.48）（p <0.001）评估肾脏形态变化。从以上发现，可以说糖尿病引起的肾病可能与CB1受体的过表达有关，而阻断CB1受体可能在减轻糖尿病引起的肾病方面是有益的。